CD38-Targeted Theranostics of Lymphoma with (89)Zr/(177)Lu-Labeled Daratumumab.
CD38-Targeted Theranostics of Lymphoma with (89)Zr/(177)Lu-Labeled Daratumumab.
复制标题
使用 Zr-89/Lu-177 标记的 Daratumumab 对淋巴瘤进行 CD38 靶向治疗诊断
DOI：
10.1002/advs.202001879
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Cai W
中科院分区：
文献类型：
--
作者：
Kang L;Li C;Rosenkrans ZT;Huo N;Chen Z;Ehlerding EB;Huo Y;Ferreira CA;Barnhart TE;Engle JW;Wang R;Jiang D;Xu X;Cai W
淋巴瘤是一种异质性疾病，具有不同的临床表现和结果。伯基特淋巴瘤和弥漫性大B细胞淋巴瘤等多种淋巴瘤具有高度的侵袭性，即使在常规化疗和放疗后，预后也很差。因此，探索淋巴瘤的特异性生物标志物具有很高的临床意义。在此，一个潜在的标志物，CD 38，研究用于区分淋巴瘤。然后用Zr-89和Lu-177对靶向CD 38的单克隆抗体（mAb，daratumumab）进行放射性标记，用于治疗诊断。作为诊断成分，Zr-89标记的mAb在通过正电子发射断层扫描（PET）成像描绘CD 38阳性淋巴瘤方面具有高度特异性，而Lu-177标记的mAb作为治疗成分在一次性给药后可抑制肿瘤生长。这些结果强烈表明，CD 38是淋巴瘤特异性标志物，并证明89 Zr/177 Lu标记的达雷妥尤单抗有助于临床前模型中淋巴瘤的免疫PET成像和放射免疫治疗。这种CD 38靶向治疗诊断学的进一步临床评价和翻译可能对淋巴瘤患者分层和管理有重要帮助。靶向CD 38的单克隆抗体（mAb，daratumumab）用Zr-89和Lu-177进行放射性标记，用于治疗诊断。作为诊断组分，Zr-89标记的mAb在通过正电子发射断层扫描成像描绘CD 38阳性淋巴瘤方面具有高度特异性，而Lu-177标记的mAb作为治疗组分在一次性给药后可有效抑制肿瘤。进一步的临床翻译可能对淋巴瘤具有重要意义。
Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional chemotherapy and radiotherapy. As such, exploring specific biomarkers for lymphoma is of high clinical significance. Herein, a potential marker, CD38, is investigated for differentiating lymphoma. A CD38‐targeting monoclonal antibody (mAb, daratumumab) is then radiolabeled with Zr‐89 and Lu‐177 for theranostic applications. As the diagnostic component, the Zr‐89‐labeled mAb is highly specific in delineating CD38‐positive lymphoma via positron emission tomography (PET) imaging, while the Lu‐177‐labeled mAb serves well as the therapeutic component to suppress tumor growth after a one‐time administration. These results strongly suggest that CD38 is a lymphoma‐specific marker and prove that 89Zr/177Lu‐labeled daratumumab facilitates immunoPET imaging and radioimmunotherapy of lymphoma in preclinical models. Further clinical evaluation and translation of this CD38‐targeted theranostics may be of significant help in lymphoma patient stratification and management. A CD38‐targeting monoclonal antibody (mAb, daratumumab) is radiolabeled with Zr‐89 and Lu‐177 for theranostics. As the diagnostic component, the Zr‐89‐labeled mAb is highly specific in delineating CD38‐positive lymphoma via positron emission tomography imaging, while the Lu‐177‐labeled mAb serves well as the therapeutic component to suppress tumor after a one‐time administration. Further clinical translation may be of high significance for lymphoma.
登录
查看更多内容
DOI：
10.3322/caac.21438
发表时间：
2018-03
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Shanbhag S;Ambinder RF
通讯作者：
Ambinder RF
影响因子：
5.6
作者：
Gudkov SV;Shilyagina NY;Vodeneev VA;Zvyagin AV
通讯作者：
Zvyagin AV
如（89）ZR-利妥昔单抗免疫-PET所预测的CD20+ B细胞淋巴瘤中（90）Y-利妥昔单抗在CD20+ B细胞淋巴瘤中的肿瘤靶向和辐射剂量：未经标记的Rituximab对预加载的影响。
DOI：
10.1007/s00259-015-3025-6
发表时间：
2015-07
影响因子：
9.1
作者：
Muylle, Kristoff;Flamen, Patrick;Vugts, Danielle J.;Guiot, Thomas;Ghanem, Ghanem;Meuleman, Nathalie;Bourgeois, Pierre;Vanderlinden, Bruno;van Dongen, Guus A. M. S.;Everaert, Hendrik;Vaes, Melanie;Bron, Dominique
通讯作者：
Bron, Dominique
使用 Zr-89/Lu-177 标记的 Daratumumab 对淋巴瘤进行 CD38 靶向治疗诊断
DOI：
10.1002/advs.202001879
发表时间：
2021-05
期刊：
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
影响因子：
--
作者：
Kang L;Li C;Rosenkrans ZT;Huo N;Chen Z;Ehlerding EB;Huo Y;Ferreira CA;Barnhart TE;Engle JW;Wang R;Jiang D;Xu X;Cai W
通讯作者：
Cai W
影响因子：
28.5
作者：
Sanchez L;Wang Y;Siegel DS;Wang ML
通讯作者：
Wang ML